Acorda Therapeutics acquires CeNeS neuregulin products

Hawthorne, NY November 14, 2002 Acorda Therapeutics announced today that it has acquired an exclusive worldwide license from CeNeS plc (LSE: CEN) to its neuregulin products, glial growth factor 2 (GGF2), and neuregulin 2 (NRG2), a class of therapeutic agents that has been demonstrated to promote remyelination in animal studies.

Acorda expects to advance pre-clinical development immediately on GGF2, in preparation for human clinical trials in multiple sclerosis (MS). The earlier stage product, NRG2, has potential applications in MS, spinal cord injury (SCI), Parkinson's disease and chronic heart failure. Acorda will also expand the existing, widespread network of academic collaborators involved in this high-potential area of CNS research.

Ron Cohen, M.D., Acorda's President and CEO said, "This acquisition adds an important new product to our existing remyelination program, which includes the M1 remyelinating monoclonal antibody technology. Together, these technologies give Acorda a dominant position in remyelinating therapeutics. Current MS therapies work by slowing the progression of the disease but do not address the permanent demyelination that leads to the disabilities associated with that condition. Neuregulins act to stimulate the regrowth of myelin, thereby offering an entirely new type of therapeutic agent than ones currently available for MS. The neuregulins also have potential to be therapeutic in other acute or degenerative disorders of the CNS, such as SCI, peripheral neuropathies and Parkinson's disease."

About Neuregulins

Neuregulin-1 is a gene, the products of which include Glial Growth Factor 2 (GGF2). GGF2 is known to stimulate the growth and differentiation of glial cells, the support cells of the nervous system. These glial cells form the myelin sheath that insulates nerve cells and is essential for their proper functioning. In demyelinating diseases such as multiple sclerosis, the myelin sheath is damaged or l

Contact: Tierney Saccavino, Acorda Therapeutics
Porter Novelli

Page: 1 2 3

Related biology news :

1. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
2. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
3. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
4. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
5. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
7. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
8. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
9. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. Immerge BioTherapeutics announces identification of PERV receptor

Post Your Comments:

(Date:11/12/2019)... ... November 12, 2019 , ... ... design and manufacturer of technical ergonomic seating solutions, announced this week that ... Healthier Hospital Initiative guidelines. Established by Practice Greenhealth, a health care membership ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... and water purifiers, announced today that distributors voted their patented automatic and manual ... ® water purifiers. , The most frequent maintenance task required of an ultraviolet ...
(Date:11/9/2019)... THURMONT, Md. (PRWEB) , ... ... ... merged with Alizée Pathology to form the leading provider of specialized histology, ... contract research industries. StageBio was recently created by the mergers of Histo-Scientific ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... Peggy Lillis ... about the deadly healthcare-associated infection C. diff. The campaign, “See C. diff,” ... which kills at least 30,000 people in the U.S. each year. The campaign ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By ... the Fusion Bx 2.0 will give urologists across Europe the ability to perform ...
(Date:10/30/2019)... ... October 30, 2019 , ... While using cold plasma to kill cancer cells ... Dakota School of Mines & Technology are exploring new ways to regulate cold ... , If successful, the technique would prove to be a drug-free, minimally invasive cancer ...
(Date:10/26/2019)... ... October 24, 2019 , ... ... Bichsel Medical Marketing Group (BMMG), a boutique healthcare-specific marketing firm, to strengthen ... its in-house Healthcare Strategy Division. , Healthcare clients in pharma, bio-therapeutics, medical device ...
Breaking Biology Technology:
Cached News: